Meetings, Workshops and Congressional Testimony:
Wednesday, 7/1 – Thursday, 7/2 –
The FDA’s Center for Drug Evaluation and Research, in collaboration with the National Institutes of Drug Abuse, the CDC, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, will host a public meeting, Exploring Naloxone Uptake and Use
. The meeting will initiate a public discussion surrounding the uptake of naloxone in certain medical settings as well as outside of conventional medical settings to reduce the incidence of opioid overdose fatalities. Academia, government, industry experts, and patient advocates will discuss which populations are at risk for opioid overdose and how public health groups can work together to use naloxone to reduce the risk of overdose. The meeting will take place beginning at 8 a.m. on both days at the FDA’s White Oak campus, Silver Spring, Maryland.
In Case You Missed It:
Thursday, 6/25 –
FDA Voice Blog: Thinking About FSMA Issues
. Implementation of the FDA Food Safety Modernization Act involves people at all segments of the food supply chain, from farm to table. On April 23-24, 2015, the FDA held a public meeting in Washington D.C. to discuss its plans to implement FSMA rules designed to build a food safety system that focuses on prevention and risk.
Tuesday, 6/23 –
Consumer Update: Kids and Tobacco Use: Some Surprising Findings
. The number of kids smoking cigarettes is down—but the number using other tobacco products is way up. That’s the word from the 2014 National Youth Tobacco Survey, co-conducted by the CDC and the FDA.
Monday, 6/22 –
News Release: FDA approves new antiplatelet drug used during heart procedure
. The FDA approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart. It is approved for adult patients undergoing percutaneous coronary intervention, a procedure used to open a blocked or narrowed coronary artery to improve blood flow to the heart muscle.
Press Office Contact: Sarah Peddicord, 301-796-2805, email@example.com
FDA Office of Media Affairs Contact Information: